From left: Andreas Dräger, Dr. Reihaneh Mostolizadeh, Dr. Alina Renz und die Erstautorin M.Sc. Nantia Leonidou.
From left: Andreas Dräger, Dr. Reihaneh Mostolizadeh, Dr. Alina Renz und die Erstautorin M.Sc. Nantia Leonidou. Effective drugs against viral diseases like COVID-19 are urgently needed now and in the future. The emergence of viral mutants and yet unknown viruses could push vaccines to their limits. The DZIF scientist and bioinformatician Andreas Dräger from the University of Tübingen is working on a computer-based method that can help to accelerate the time-consuming identification and development of antiviral agents. Using a novel analysis technique that applies to any virus and host cell type, the research team around Dräger has now created a model to detect additional host cell targets that allow inhibiting SARS-CoV-2 replication. -Efficient pandemic preparedness requires new, broadly effective antiviral drugs against which the viruses cannot quickly develop resistance,- explains Andreas Dräger, junior professor at the Univer-sity of Tübingen and member of the Tübingen Cluster of Excellence -Controlling Microbes to Fight Infections - CMFI-.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
